Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 855 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Proton beam radiation therapy. Clear all
Recruiting Phase 2 Interventional

Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)

NCT06706258
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

NCT01730950
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
bevacizumab, radiation therapy
Biological · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Walnut Creek, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer

NCT01821729
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Losartan, Proton Beam Radiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated No phase listed Observational

Proton Radiation Therapy for Pituitary Adenoma

NCT00798057
View directory record Official record
Conditions
Pituitary Adenoma
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)

NCT05524844
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Sample Collection, Endoscopy results, Dietary questionnaire
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 1 Interventional

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

NCT03696355
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
GDC-0084, radiation therapy
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated Not applicable Interventional

Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma

NCT03843814
View directory record Official record
Conditions
Gliosarcoma, Glioma
Interventions
APT MRI
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Phase 1 Interventional

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

NCT06058663
View directory record Official record
Conditions
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Angiography, Biopsy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Positron Emission Tomography, Tremelimumab, Yttrium-90 Microsphere Radioembolization
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Phase 2 Interventional

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

NCT05890352
View directory record Official record
Conditions
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Tafasitamab, Tazemetostat, Zanubrutinib
Procedure · Drug · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
104
States / cities
Tucson, Arizona • Beverly Hills, California • Duarte, California + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 15, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PPI and Clopidogrel Response

NCT01170533
View directory record Official record
Conditions
Drug Interaction
Interventions
omeprazole and pantoprazole
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle

NCT01266577
View directory record Official record
Conditions
Brain Mapping, Healthy Volunteer
Interventions
NSR MAGNETOM 7T, 1Tx x 32Rx Head Coil
Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional

A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck

NCT07644585
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ConformalFLASH irradiation
Radiation
Lead sponsor
IBA Proton Therapy, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated Phase 1 Interventional

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

NCT01165658
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Carcinoid, Thymic Cancer, Lung Cancer
Interventions
Proton Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 15, 2026, 1:41 AM EDT
Suspended Phase 1Phase 2 Interventional

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050
View directory record Official record
Conditions
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Completed No phase listed Observational

Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy

NCT02404818
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Cardiac Magnetic Resonance Imaging, Echocardiogram
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 15, 2026, 1:41 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

NCT04842890
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pencil Beam Scanning Proton SBRT
Radiation
Lead sponsor
The New York Proton Center
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Terminated Phase 1 Interventional

Proton Therapy and Bevacizumab for Primary Liver Tumors

NCT00426829
View directory record Official record
Conditions
Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
Interventions
Bevacizumab, Proton Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Phase 1 Interventional

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT06675123
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, BTK Inhibitor, Computed Tomography, Pacritinib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Phase 2 Interventional

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

NCT06319027
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate, Magnetic Resonance Spectroscopy, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Recruiting Early Phase 1 Interventional

Pencil Beam Scanning in Patients With Renal Tumors

NCT03810651
View directory record Official record
Conditions
Renal Tumor, Wilms Tumor
Interventions
Proton beam radiation using pencil beam scanning
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 30 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 1:41 AM EDT
Suspended Phase 1Phase 2 Interventional

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

NCT06572605
View directory record Official record
Conditions
Extramedullary Disease in Multiple Myeloma, Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, External Beam Radiation Therapy, Image Guided Biopsy, Positron Emission Tomography, Talquetamab
Procedure · Other · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 1:41 AM EDT